AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
With over 30 years of experience in all phases of tissue targeted, sustained release pharmaceutical formulation development, the firm’s founder, President and CEO Dr. Shikha P. Barman, and company R&D Head Kevin Ward, will be on hand to discuss the specific requirements of interested attendees.
ABOUT INTEGRAL BIOSYSTEMS
Integral BioSystems is a specialty drug delivery contract research organization that offers an integrated, practical approach to formulation development projects for both small molecule and large molecule drug candidates. Offering contract services to pharmaceutical companies to develop drug products through its CMC offerings in analytical method development, formulation development, process development, scale-up and technology transfer, the company also partners with pharmaceutical companies to co-develop products based on its proprietary pharmaceutical delivery systems. For those seeking to develop a formulation for a new drug substance, a 505b2 product or a generic drug product, Dr. Barman will be available to answer questions about the suitability of Integral’s recently patented drug delivery platform technologies NanoM-Wafer™ and OcuHeal™ for your particular application.
The Company has developed numerous dosage forms for ophthalmic applications. Integral BioSystems has a translational approach to drug development, customizing delivery systems to achieve the biologically effective objectives of the therapy. Dosage forms are customized to achieve sustained release or targeted, tissue-focused delivery or fast-release/instant delivery, depending upon the desired product attributes. The company offers rapid proof-of-concept feasibility formulations or development toward IND submission, including cGLP services.
ABOUT THE SYMPOSIUM
The ARVO 2025 Annual Meeting of the Association for Research in Vision and Ophthalmology will cover pioneering and current R&D on pharmacological therapies-in-development to treat ocular disorders, in both anterior and posterior segments of the eye. This gathering of scientists, medical personnel, and representatives from related businesses combines a wide range of talks from commercial and academic figures in ophthalmological science, poster presentations about recent developments in ophthalmology, and offers of ophthalmology-related products and services. It is anticipated that approximately 11,000 people will participate in this meeting.
Dave Karasic
Integral BioSystems, LLC
+1 617-820-8483
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
